middl
east
respiratori
syndrom
mer
caus
mer
coronaviru
merscov
march
affect
countri
case
least
sensit
serolog
assay
independ
use
live
merscov
biosafeti
level
laboratori
import
clinic
diagnosi
research
recombin
antigenbas
enzymelink
immunosorb
assay
elisa
prefer
diagnosi
owe
high
effici
reproduc
importantli
assay
requir
cultiv
merscov
biosafeti
level
facil
readili
avail
laboratori
although
elisa
kit
commerci
avail
use
mani
data
limit
compar
elisa
detect
merscov
antibodi
human
base
altern
recombin
antigen
includ
extracellular
domain
repres
fulllength
spike
protein
ntermin
domain
ntd
receptorbind
domain
rbd
nucleoprotein
np
use
seri
sera
first
import
case
mer
china
longitudin
evalu
antibodi
product
compar
antigen
whole
inactiv
merscov
ntd
rbd
np
sera
also
use
investig
correl
elisa
pseudoviru
particlebas
neutral
test
ppnt
first
merscov
case
china
import
republ
korea
confirm
hospit
admiss
end
may
case
investig
reveal
histori
exposur
first
confirm
mer
case
south
korea
male
patient
question
visit
father
admit
hospit
ward
korean
patient
merscov
may
korea
patient
complain
feel
unwel
respiratori
symptom
temperatur
may
howev
day
later
medic
advic
travel
south
korea
guangdong
provinc
mainland
china
via
hong
kong
may
chines
ministri
health
notifi
patient
entri
china
world
health
organ
man
confirm
merscovposit
may
immedi
admit
discharg
hospit
end
june
seri
venou
blood
sampl
collect
patient
admit
hospit
normal
control
sera
healthi
blood
donor
sex
use
detect
background
valu
calcul
cutoff
valu
method
use
studi
blood
sampl
process
within
h
collect
sera
store
merscov
strain
kindli
provid
professor
ron
fouchier
erasmu
medic
centr
rotterdam
netherland
viru
propag
vero
cell
atcc
manassa
va
usa
dulbecco
modifi
eagl
medium
supplement
fetal
calf
serum
intern
unitsml
penicillin
streptomycin
experi
relat
live
merscov
perform
accord
standard
oper
procedur
biosafeti
facil
chines
center
diseas
control
prevent
china
cdc
quantifi
merscov
inactiv
formaldehyd
seven
day
inactiv
merscov
centrifug
rpm
min
collect
supernat
confirm
noninfecti
titrat
vero
cell
subsequ
supernat
concentr
centrifug
rpm
h
pellet
collect
dissolv
phosphatebuff
salin
pb
overnight
concentr
merscov
quantifi
use
bcabas
protein
quantif
kit
applygen
technolog
inc
beij
china
store
use
addit
inactiv
merscov
character
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
western
blot
wb
assay
recombin
histag
extracellular
domain
amino
acid
merscov
spike
express
cell
purchas
sino
biolog
inc
beij
china
construct
express
plasmid
rbd
amino
acid
merscov
method
use
subsequ
express
cell
describ
ntd
amino
acid
express
cell
provid
institut
microbiolog
chines
academi
scienc
express
purif
np
prokaryot
system
perform
describ
purifi
ntd
rbd
np
identifi
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
wb
elisa
plate
coat
overnight
inactiv
merscov
particl
recombin
protein
ngwell
carbon
buffer
ph
well
plate
incub
block
solut
consist
goat
serum
pb
two
h
well
wash
five
time
pb
contain
tween
pbst
aliquot
serial
dilut
sera
ad
well
elisa
plate
follow
incub
h
five
wash
pbst
plate
incub
horseradish
peroxidas
hrp
label
goat
antihuman
immunoglobulin
g
igg
igm
antibodi
one
h
sigma
st
loui
mo
usa
ad
five
wash
pbst
well
incub
min
room
temperatur
ad
well
termin
reaction
optic
densiti
od
immedi
read
nm
averag
valu
normal
control
calcul
igg
igm
cutoff
valu
determin
averag
normal
sd
normal
control
sera
mix
equal
volum
serv
neg
control
elisa
kit
detect
igg
purchas
euroimmun
luebeck
germani
analys
perform
accord
manufactur
instruct
kit
includ
calibr
defin
cutoff
valu
recommend
manufactur
valu
cutoff
consid
neg
consid
posit
igm
level
determin
use
elisa
kit
determin
outsid
rang
applic
kit
pseudoviru
express
merscov
protein
prepar
use
envdefect
luciferaseexpress
genom
ppnt
perform
describ
briefli
lentivirusbas
merscov
pseudoviru
preincub
serial
dilut
serum
sampl
patient
merscov
one
h
mixtur
distribut
plate
contain
monolay
cell
h
incub
fresh
medium
ad
follow
incub
addit
h
cell
wash
pb
lyse
use
lysi
reagent
includ
luciferas
kit
promega
madison
wi
usa
aliquot
cell
lysat
transfer
costar
flatbottom
luminometri
plate
corn
costar
corn
ny
usa
follow
addit
luciferas
substrat
promega
rel
fluoresc
intens
valu
immedi
determin
use
gaomax
luminomet
promega
luciferas
activ
cell
treat
pseudoviru
alon
refer
group
defin
infect
cell
treat
pseudoviru
includ
background
control
result
express
percentag
infect
compar
control
group
cell
treat
pseudoviru
prepar
fifti
percent
reduct
rel
fluoresc
intens
use
calcul
merscovspecif
neutral
antibodi
nab
titer
sera
nab
titer
defin
highest
serum
dilut
result
reduct
luciferas
activ
nab
titer
lower
consid
neg
experi
perform
least
three
time
data
analyz
use
spss
ibm
new
york
ny
usa
graphpad
prism
graphpad
softwar
inc
la
jolla
ca
usa
pearson
correl
coeffici
differ
assay
calcul
signific
defin
p
inactiv
merscov
character
wb
shown
contain
np
viral
compon
supplementari
figur
purifi
ntd
rbd
np
found
highli
pure
antigen
wb
supplementari
figur
normal
control
ie
sera
healthi
blood
donor
use
determin
background
valu
calcul
cutoff
level
igg
igm
inactiv
merscov
ntd
rbd
np
igg
control
sera
detect
elisa
cutoff
valu
determin
supplementari
figur
longitudin
profil
bind
antibodi
igg
igm
nab
merscov
sera
first
case
import
merscov
china
analyz
depend
whole
merscov
recombin
protein
elisa
ppnt
figur
show
elisa
readili
detect
specif
antibodi
patient
sera
merscov
sbase
elisa
show
highest
sensit
follow
rbdbase
elisa
inactiv
merscov
ntd
npbase
elisa
sensit
rbdbase
elisa
moreov
rbdbase
elisa
show
broader
measur
rang
base
inactiv
merscov
ntd
np
ppnt
assay
nab
posit
appear
earli
anti
antibodi
posit
determin
elisa
figur
anti
antibodi
first
detect
elisa
igm
day
igg
day
admiss
follow
antibodi
rbd
antibodi
merscov
particl
ntd
final
antibodi
np
day
admiss
supplementari
figur
whole
virusbas
elisa
kit
abl
detect
antibodi
specif
structur
compon
viru
present
studi
correl
recombin
proteinbas
elisa
base
inactiv
merscov
analyz
scatter
plot
figur
show
excel
correl
merscov
elisa
rbd
np
elisa
pearson
correl
coeffici
ntd
elisa
less
strongli
correl
merscov
elisa
pearson
correl
coeffici
subsequ
correl
ntd
rbd
elisa
result
commerci
elisa
examin
scatter
plot
figur
show
excel
correl
elisa
rbd
elisa
pearson
correl
coeffici
ntd
elisa
less
strongli
correl
elisa
pearson
correl
coeffici
mer
ppnt
sensit
specif
assay
use
detect
nab
merscov
examin
relationship
ppnt
variou
elisa
scatter
plot
figur
show
elisa
strong
correl
ppnt
pearson
correl
coeffici
merscov
ntd
rbd
elisa
less
strongli
correl
mer
ppnt
pearson
correl
coeffici
best
knowledg
first
comprehens
investig
antimerscov
antibodi
profil
sera
mer
patient
base
multiplex
analysi
antibodi
protein
np
longitudin
profil
igg
igm
antibodi
sera
case
first
import
china
show
seroconvers
antibodi
detect
rbd
elisa
occur
earlier
detect
inactiv
merscov
elisa
result
shown
figur
illustr
rbd
elisa
sensit
whole
merscov
elisa
detect
specif
antibodi
previou
sever
acut
respiratori
syndrom
coronaviru
sarscov
studi
proteinbas
elisa
also
appear
sensit
virusbas
huada
elisa
detect
sarscovspecif
np
sarscov
immunodomin
antigen
use
detect
sarscov
present
studi
npbase
elisa
illustr
benefit
use
recombin
np
detect
merscov
infect
howev
seroconvers
npspecif
antibodi
occur
later
seroconvers
antibodi
sever
protein
inactiv
merscov
woo
et
evalu
longitudin
profil
igg
igm
antibodi
sarscov
np
patient
pneumonia
due
sarscov
studi
show
level
two
antibodi
increas
detect
level
third
week
ill
approxim
week
later
observ
anoth
studi
lie
et
base
whole
sarscov
elisa
delay
seroconvers
npspecif
antibodi
studi
woo
et
compar
result
li
et
may
reflect
reduc
sensit
npbase
elisa
base
inactiv
viru
particl
detect
sarscov
infect
earli
stage
ill
although
clinic
treatment
may
also
interfer
appear
antibodi
result
two
studi
confirm
characterist
npspecif
antibodi
differ
context
woo
et
report
igm
antibodi
sarscov
np
increas
detect
level
later
igg
antibodi
contrast
phenomena
describ
pathogen
found
igm
antibodi
antigen
detect
time
later
igg
present
studi
may
due
earlier
develop
igg
igm
antibodi
differ
sensit
ig
classspecif
elisa
kit
advantag
easi
oper
conveni
valid
appli
mani
present
studi
gradual
increas
serum
igg
antibodi
level
observ
first
patient
import
merscov
china
case
merscov
patient
studi
perform
south
kingdom
saudi
seroconvers
igg
antibodi
observ
day
admiss
day
onset
ill
consist
previou
moreov
elisa
maintain
excel
correl
inactiv
merscov
elisa
p
present
studi
recombin
rbd
main
epitop
sensit
detect
merscov
infect
excel
correl
rbd
elisa
elisa
pearson
correl
coeffici
therefor
rbd
develop
altern
antigen
elisa
kit
detect
merscov
infect
mersspik
ppnt
assay
prefer
owe
lack
requir
biosafeti
level
facil
use
extens
valid
seroepidemiolog
human
good
correl
mer
ppnt
present
studi
confirm
sensit
ppnt
use
detect
nab
earli
stage
ill
moreov
ppnt
assay
show
excel
correl
elisa
although
latter
bind
assay
former
function
neutral
assay
merscov
ntd
rbd
elisa
accept
lower
pearson
correl
coeffici
compar
ppnt
titer
specul
multipl
compon
irrelev
neutral
inactiv
merscov
fewer
epitop
relat
neutral
recombin
ntd
rbd
studi
certain
limit
studi
one
patient
follow
one
month
admiss
hospit
although
one
merscov
case
report
china
addit
case
longer
followup
need
comprehens
understand
merscovderiv
antibodi
profil
verifi
specif
sensit
merscov
recombin
proteinbas
elisa
fortun
seri
serum
sampl
collect
case
addit
commerci
elisa
kit
avail
adopt
refer
test
found
elisa
variou
recombin
structur
protein
includ
ntd
rbd
np
well
ppnt
assay
use
merscov
diagnosi
seroepidemiolog
rbd
elisa
sensit
elisa
format
especi
rbd
elisa
advantag
recombin
rbd
smaller
fulllength
easier
express
purifi
conclus
rbd
elisa
may
altern
elisa
determin
infect
earli
stage
patient
poor
serolog
respons
merscov
addit
elisa
may
use
altern
mer
ppnt
shown
reliabl
surrog
neutral
activ
may
use
largescal
seroepidemiolog
studi
merscov
infect
